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Abstract
Aims To analyse glucose-lowering drug utilization, focusing on the novel glucose-lowering drug groups dipeptidyl
peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors, and the
financial burden they entail.
Methods Crude reimbursed national drug utilization and expenditure data for the entire population of Hungary were
obtained from the National Health Insurance Fund for the study period: 2008 to 2017. Data were analysed using the
WHO’s Anatomical Therapeutic Chemical Classification/defined daily dose system and were expressed in defined daily
dose per 1000 inhabitants per day.
Results Total glucose-lowering drug consumption in Hungary showed an 18% increase over the study period, reaching
74.7 defined daily doses per 1000 inhabitants per day, while novel glucose-lowering drug use increased to 11.7 defined
daily doses per 1000 inhabitants per day (16% of total glucose-lowering drug use) by 2017. Dipeptidyl-peptidase 4
inhibitor consumption grew to 7.4 defined daily doses per 1000 inhabitants per day by 2017. The most widely used
dipeptidyl-peptidase 4 inhibitor was sitagliptin. Glucagon-like peptide-1 receptor agonists were used the least, but by
2017 rose to 1.5 defined daily doses per 1000 inhabitants per day, led by liraglutide. Sodium-glucose co-transporter-2
inhibitors appeared in the utilization data in 2014 and their consumption, mainly empagliflozin, reached 2.8 defined
daily doses per 1000 inhabitants per day by 2017. The total expenditure on glucose-lowering drugs increased 94%
between 2008 and 2017, and the total cost of novel glucose-lowering drug utilization comprised 44% of the total
glucose-lowering drug expenditure in 2017.
Conclusions Both the use of and the financial burden posed by novel glucose-lowering drugs in Hungary increased
steadily between 2008 and 2017. This increase is expected to continue.
Diabet. Med. 36, 1612–1620 (2019)
Introduction
Diabetes mellitus is a growing health problem. The global
prevalence of diabetes has almost doubled in the last 30–40
years (4.7% in 1980 and 8.5% in 2014); in Hungary the
prevalence of people diagnosed with diabetes reached 10%
in 2015 [1,2]. As the global burden of diabetes has increased,
diabetes management has received increasing attention.
According to therapeutic recommendations, lifestyle changes
(including nutrition therapy, physical activity, smoking
cessation and education) are essential to type 2 diabetes
management, alongside optimal pharmacotherapy [3]. While
for type 1 diabetes insulin preparations play the main role in
pharmacotherapy, pharmacological treatment options for
type 2 diabetes are more diverse and have changed consid-
erably. Although metformin remains the first-line agent,
novel glucose-lowering drugs—dipeptidyl peptidase-4 (DPP-
4) inhibitors, glucagon-like peptide-1 receptor agonists
(GLP-1RAs) and sodium-glucose co-transporter-2 (SGLT2)
inhibitors—have been developed, authorized and included in
therapeutic guidelines and recommendations [3,4]. In Hun-
gary, such drugs receive reimbursement from the National
Health Insurance Fund [5].
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Drug utilization studies are essential to evaluate the trends
and changes in medication use. They also provide the
opportunity to explore how the availability of new drug
groups may reshape prescribing patterns in certain health
conditions. Although studies on glucose-lowering drug uti-
lization changes have been conducted in Hungary and in
several other countries, in recent years the use of novel
glucose-lowering drug groups specifically has not yet been
analysed in detail in Hungary [6–8].
In the present study, our aim was to analyse the changes in
utilization of glucose-lowering medications, focusing on
changes in consumption of novel glucose-lowering drug
groups, and to explore the financial burden generated by
these products in Hungary between 2008 and 2017.
Methods
Retrospective drug utilization analysis was conducted cov-
ering the period between 2008 and 2017. The data were
obtained from the medication dispensing database of the
Hungarian National Health Insurance Fund, the sole and
mandatory health insurance provider in Hungary [5]. The
National Health Insurance Fund database contains the
following monthly aggregated utilization data on each
reimbursed medication for the entire population of Hungary
(nearly 10 million people): name of drug; strength; package
size; Anatomical Therapeutic Chemical Classification (ATC)
code; active ingredient; reimbursement category; number of
boxes; total retail cost; and total reimbursement cost. In the
case of reimbursed medication, the total retail cost is shared
between the National Health Insurance Fund (reimburse-
ment cost) and the individual with diabetes (co-payment).
The data were analysed using the WHO ATC/defined daily
dose (DDD) system (version 2018) and were expressed in
DDD per 1000 inhabitants per day (DDD/TID) [9]. DDD is
the assumed averagemaintenance daily dose of themedication
used for its main therapeutic indication in adults and DDD/
TID is calculated with the following formula: [amount used in
1 year (mg) 9 1000]/[DDD (mg) 9 population 9 365] [9].
Using the technical unit DDD/TID enables researchers to
express the use of drugs in a standardized way and makes it
possible to compare medication use across populations of
different sizes. DDD/TID may also give a rough estimation of
the proportion of the population using a certain medication.
For example, 10 DDD/TID can be interpreted as, on average,
1% of the population using the medication every day [10].
For the present study, we analysed drugs used for diabetes
(ATC code: A10) with special emphasis on novel glucose-
lowering drug groups. Regarding these novel glucose-
lowering drug groups, medications with the following ATC
codes were included: A10BH and A10BD07-13 for DPP-4
inhibitors; A10BJ, A10AE54 and A10AE56 for GLP-1RAs;
A10BK, A10BD15 and A10BD20 for SGLT2 inhibitors.
Descriptive statistics were used to describe the sum of
yearly medication use, and relative use was expressed as the
proportion of total glucose-lowering drug use. Linear
regression was applied to analyse trends in the consumption
of glucose-lowering drug groups in cases where data for a
minimum 5 years were available. Trends were described by
the regression coefficient (average annual change) and
significance (P value) of the regression coefficient. P values
<0.05 were taken to indicate statistical significance.
Microsoft Access and Microsoft Excel (Microsoft Office
2010, Microsoft Corp., Redmond, WA, USA) and R (version
3.6.0, R Foundation for Statistical Computing Vienna,
Austria) programs were used for data analysis.
Ethics
The data were aggregated and anonymous, therefore, ethical
approval was not required.
Results
Utilization trends of glucose-lowering drugs
During the 10-year study period, the consumption of
glucose-lowering drugs showed an 18% increase and reached
74.7 DDD/TID, although in 2015, there was a drop in total
glucose-lowering medication use (Table 1). Total insulin use
rose by 41%, to 26.4 DDD/TID in 2017. Sulfonylureas were
used most frequently in 2008, but from 2009 their use
decreased consistently, with a 25% decrease by 2017. The
consumption of biguanides as monocomponent preparations
fluctuated; after a considerable increase, there was a rapid
decrease in 2015. In the following years, consumption
slightly increased again, and in 2017, biguanide use was
13.9 DDD/TID. Metformin fixed-dose combination products
have begun to play an increasing role and reached 6.9 DDD/
TID by 2017. a-glucosidase inhibitors, thiazolidinediones
What’s new?
• The use of glucose-lowering drugs has increased con-
tinuously over the past decade. Since 2008 the use of
these medications in Hungary [expressed in defined
daily dose per 1000 inhabitants per day (DDD/TID)]
has grown by 18%.
• The use of novel glucose-lowering drug groups (dipep-
tidyl peptidase-4 inhibitors, glucagon-like peptide-1
receptor agonists and sodium-glucose co-transporter-2
inhibitors) has steadily increased, reaching 16% of the
total glucose-lowering drug consumption (expressed in
DDD/TID) in 2017.
• The total expenditure on glucose-lowering medicines
has increased by 94% since 2008. Novel glucose-
lowering drug use places a high financial burden both
on people with diabetes and the healthcare system.
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and meglinides were less commonly used and their con-
sumption steadily decreased over the study period (Table 1).
Utilization trends of novel glucose-lowering drugs
From 2008, total novel glucose-lowering drug use increased
constantly and significantly, from 0.04 DDD/TID to 11.7
DDD/TID, which was the largest increase among all glucose-
lowering drug groups during the study period (Table 1). The
proportion of novel glucose-lowering drugs rose to 16% of
total glucose-lowering medication use by 2017 (Table 2).
During the past 10 years, the most widely used novel
glucose-lowering drug group comprised the DPP-4 inhibi-
tors, which first appeared on the Hungarian market in 2008.
Their consumption showed dynamic growth and reached 7.4
DDD/TID in 2017 (Table 2). Aggregated DPP-4 inhibitor
use was 64% of the total novel glucose-lowering drug
consumption in 2017. While sitagliptin monocomponent
products constituted the majority of DPP-4 inhibitor use in
2008, in 2017 three-quarters of the total DPP-4 inhibitor use
was fixed-dose preparations with metformin. Regarding
fixed-dose combinations, metformin + sitagliptin was used
the most frequently in 2017, but metformin + vildagliptin
and metformin + linagliptin consumption was also notable.
Saxagliptin and alogliptin and their fixed-dose combinations
with metformin were rarely used and, in recent years,
utilization decreased (Table 2).
Among the novel glucose-lowering drugs, GLP-1RAs
accounted for the lowest utilization rates, although they did
show an increase in use over time. GLP-1RAs appeared in the
National Health Insurance Fund database in 2010 and, by
2017, their use was 1.5 DDD/TID, 13% of total novel glucose-
lowering drug consumption. Fixed-ratio combinations (mainly
insulin degludec + liraglutide and less often insulin glargine +
lixisenatide) represented one-third of the total GLP-1RA
consumption, while monocomponent medications represented
two-thirds of GLP-1RA utilization in 2017. The most com-
monly used monocomponent product in 2017 was liraglutide,
followed by dulaglutide, lixisenatide and exenatide (Table 2).
Although SGLT2 inhibitors appeared in the utilization data
only in 2014, their total consumption grew to 2.8 DDD/TID
during the subsequent 4-year period and accounted for 24% of
total novel glucose-loweringdruguse in2017.Theutilizationof
monocomponent SGLT2 inhibitor preparations increased
dynamically and reached 1.5 DDD/TID, while the use of
SGLT2 inhibitors + metformin was slightly lower in 2017.
Approximately two-thirds of the total SGLT2 inhibitor utiliza-
tion comprised empagliflozin and its combinations (Table 2).
Financial burden of novel glucose-lowering drugs
The increased utilization of novel glucose-lowering drugs has
resulted in higher healthcare expenditure for both individuals
with diabetes and the National Health Insurance Fund
because these drugs have a considerably higher price than
other glucose-lowering drugs. Comparing the average retail
prices (reimbursement + co-payment) per DDD, among
subcutaneous preparations, GLP-1RAs are 4.4–5.7 times
more expensive than human insulins. Among oral glucose-
lowering drugs, DPP-4 inhibitors cost 12.3–15.4 times more
than metformin, and SGLT2 inhibitors are 14.6 times more
expensive than metformin. Total expenditure on glucose-
lowering medications has increased by 94% since 2008,
reaching 50.04 bn HUF (EUR 161.4 m) in 2017. Within total
glucose-lowering medication expenditure, the share of novel
glucose-lowering drugs has grown substantially. By 2017, the
total cost of novel glucose-lowering drug utilization
accounted for 44% of the total glucose-lowering medication
expenditure (Fig. 1). As all novel glucose-lowering drugs
were reimbursed medications, both the health insurance
provider’s and individuals’ expenditure on these drugs have
risen significantly since 2008, but to a different extent. In
2017, novel glucose-lowering drugs comprised a 39% share
of the National Health Insurance Fund’s total reimbursement
expenditure on glucose-lowering drugs, while 63% of co-
payment for glucose-lowering drugs was spent on novel
glucose-lowering drugs (Fig. 1).
Discussion
The present retrospective analysis of the changes in glucose-
lowering medication use in Hungary between 2008 and 2017
shows that glucose-lowering medication utilization patterns
have changed remarkably during the last 10 years. Since
2008, novel glucose-lowering drugs and their fixed-dose
combinations have constituted a major proportion of total
glucose-lowering medication use. Soon after being approved
for use, novel glucose-lowering drugs were included in
therapeutic recommendations made both internationally
and by the Hungarian Diabetes Association, which has
contributed to their increasing utilization [11–13]. The
Hungarian diabetes therapeutic guidelines included DPP-4
inhibitors and GLP-1RAs as early as 2009, when only
exenatide was available. At that time, they were not listed as
preferred agents, but only as options to be used in combi-
nation with metformin or sulfonylureas as a second or a third
drug [14]. SGLT2 inhibitors first appeared in the Hungarian
therapeutic guidelines in 2014, but only as an option
combined with metformin [15]. In contrast, the latest
guidelines include DPP-4 inhibitors as preferred agents in
case of metformin intolerance or contraindication [4]. If
people with diabetes do not achieve the recommended
glycaemic targets while receiving metformin monotherapy,
the Hungarian guidelines include any of the novel glucose-
lowering drugs as recommended agents in combination with
metformin [4]. Although the American Diabetes Association
statement in 2017 did not prioritize any novel glucose-
lowering drug group over another when used after met-
formin or in combination with metformin, suggesting instead
that drug choice should be based on individual factors, the
ª 2019 The Authors.
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2019 version does recommend that, in people with diabetes
who have established atherosclerotic cardiovascular disease
and/or chronic kidney disease, the use of SGLT2 inhibitors
and GLP-1RAs should have priority [3,16].
The increasing use of novel glucose-lowering drugs is not
unique to Hungary. Complete national glucose-lowering
medication utilization data based on wholesalers’ databases
were also available for Estonia, Finland and Norway [17–
25]. Novel glucose-lowering drug consumption in these three
countries showed a similarly increasing trend to that in
Hungary, but there are some national differences. While
novel glucose-lowering drug use was similar in Hungary and
Estonia, it was higher in Norway and even higher in Finland.
Almost all novel glucose-lowering drug groups had increas-
ing rates of use in the investigated countries, but utilization
was greatest in Finland (Table 3). In Estonia and Norway,
fixed-dose combinations of DPP-4 inhibitors + SGLT2
inhibitors were already utilized during the study period,
while in Hungary these fixed-dose combinations were not
used [17–22]; however, DPP-4 inhibitor or SGLT2 inhibitor
fixed-dose combinations with metformin or thiazolidine-
diones and GLP-1RA fixed-ratio combinations with insulins
were available in Hungary (Table 2). Novel glucose-lowering
drugs are eligible for 70% reimbursement in Hungary, while
the reimbursement rate is 61% in Norway, 65% in Finland,
and in Estonia it can be 50%, 75% or 90% depending on
different criteria (e.g. age, BMI, previous treatment) [5,26–
29]. Both in Norway and in Finland there is an annual ceiling
for co-payment; after reaching the ceiling, individuals do not
have to pay any co-payment for their medication for the
remainder of the calendar year [26,28].
In Hungary, the use of DPP-4 inhibitors has shown
continuous growth over the past 10 years, and this was the
most frequently used novel glucose-lowering drug group in
every year of the study period. Sitagliptin, the most
commonly used DPP-4 inhibitor in Hungary, was the first
available drug from this group and kept its leading position
during the last 10 years, while other DPP-4 inhibitors, such
as alogliptin and saxagliptin, appeared on the Hungarian
drug market later (2010 and 2014), and constituted only a
relatively small part of overall DPP-4 inhibitor use.
Linagliptin has a unique position among DPP-4 inhibitors.
Although it appeared in the consumption data only in 2012,
its higher use may be explained by its pharmacokinetic
properties. Linagliptin is excreted in faeces mainly
unchanged, and is therefore recommended for people with
diabetes who have renal impairment [3,4]. The higher rate of
utilization of DPP-4 inhibitor fixed-dose combinations may
be explained by their prices. The price of a fixed-dose
combined DPP-4 inhibitor product was equal to or lower
than the sum of the prices of the monocomponent products
in Hungary [5]. Additionally, using a combined product that
contains two active ingredients in one tablet is more
comfortable and practical for those who need dual therapy,
FIGURE 1 Financial burden of novel glucose-lowering drug groups: comparison of the increase in utilization of and increase in expenditure (total
cost, reimbursement and co-payment) on the novel glucose-lowering drugs as a proportion of the total reimbursed glucose-lowering drugs. Total cost
is shared between the National Health Insurance Fund (reimbursement) and individuals (co-payment). *Increase in individuals’ expenses, expressed
as the share of novel glucose-lowering drug co-payment (30% of total price) as a proportion of the total glucose-lowering drug co-payment.
**Increase of total drug expenditure (co-payment+reimbursement), expressed as the share of novel glucose-lowering drug expenditure as a
proportion of the total glucose-lowering drug expenditure. ***Increase in the expenditure of the National Health Insurance Fund, expressed as the
share of novel glucose-lowering drug reimbursement (70% of total price) as a proportion of the total glucose-lowering drug reimbursement.
****Increase in novel glucose-lowering drug use [defined daily dose per 1000 inhabitants per day (DDD/TID)] as a proportion of the total glucose-
lowering drug use (DDD/TID).
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which may result in increased persistence and adherence to
the medication [30].
The GLP-1RAs represent a specific novel glucose-lowering
drug group for type 2 diabetes that can be administered
subcutaneously; these drugs are also available in combina-
tion with insulins. GLP-1RAs, in particular, the fixed-ratio
combinations with insulins, are also the most expensive
among novel glucose-lowering drugs. Although drug group
characteristics such as their anti-hyperglycaemic potency,
beneficial cardiovascular effect and weight-lowering effect
are outstanding, and their use is steadily growing, this
increase in use is smaller than that observed for the other two
novel glucose-lowering drug groups [3,31]. Further growth
in GLP-1RA utilization is expected, however, because recent
consensus statements and recommendations advise using
GLP-1RAs, mainly liraglutide, instead of or in combination
with metformin, in case of established atherosclerotic
cardiovascular disease or obesity [3,32].
The SGLT2 inhibitor class of drugs appeared on the drug
market in 2014 and their use has been rapidly increasing in
Hungary ever since. This rapid increase is similarly observ-
able in Norway, Estonia and Finland (Table 3). SGLT2
inhibitors are the newest drugs in the treatment of type 2
diabetes mellitus, with a completely new and promising
target of action. Although dapagliflozin was the first avail-
able SGLT2 inhibitor in Hungary, empagliflozin quickly
became the considerably more popular of the two, which
may be attributed to its proven cardiovascular benefit [33].
The continuous rise of SGLT2 inhibitor use is likely in the
coming years, because of their proven benefit in case of
chronic kidney disease, heart failure and weight loss [3,32].
Although therapeutic recommendations and guidelines
should be the primary determining factor in choosing the
optimal pharmacotherapy for each individual, the price and
reimbursement rate for a medicine can considerably influence
therapy. In Hungary, all novel glucose-lowering preparations
are reimbursed at 70%, so the co-payment rate for individ-
uals is 30%, while human insulins are available with 100%
reimbursement (individuals are required to pay only a small
dispensing fee) and reimbursed oral glucose-lowering drug
groups are available with 50–55% or 70% reimbursement
rates [5]. As novel glucose-lowering drugs are partially
reimbursed, the increasing use of these preparations puts a
financial burden not only on the healthcare system, but also,
and more so, on people with diabetes. The higher cost for
individuals can be attributed to several factors. Firstly, novel
glucose-lowering drugs are expensive compared with other
glucose-lowering preparations. Secondly, although the
insurer pays 70% of the novel glucose-lowering drug price,
these preparations involve greater expense for the individual
than do cheaper drugs, such as metformin and sulfonylureas,
or other expensive but 100% reimbursed preparations, such
as human insulins. Although the insurer’s share of novel
glucose-lowering drug expenditure in relation to the total
glucose-lowering medication reimbursement is not increasing
as steeply as the individuals’ share, this increase adds up to a
considerable sum.
The decrease in use of sulfonylureas, a-glucosidase
inhibitors, thiazolidinediones and meglinides follows the
pattern observed in other countries and is in step with
Hungarian therapeutic guidelines [3,4,7,34]. Although both
the American Diabetes Association and the Hungarian
therapeutic guidelines recommend metformin as a first-line
agent in case of type 2 diabetes, in Hungary, a sudden
decrease was seen in the use of metformin in 2015 [3,4]. This
was due to the reimbursement withdrawal of one of the most
commonly prescribed metformin preparations, and conse-
quently its further use was not captured in the database.
Since metformin is also available as a fixed-dose combination
with several other oral glucose-lowering drugs, the total use
of metformin fixed-dose combinations is increasing.
The present study has both strengths and limitations. The
10-year study period enabled us to observe the appearance of
novel glucose-lowering drugs on the market and to follow
their increasing consumption. The National Health Insur-
ance Fund database contains drug dispensing data for the
entire Hungarian population; however, this database records
data only on the sale of reimbursed medications. As a result,
our data have total population coverage, but not total drug
dispensing coverage since non-reimbursed drugs are not
included in the database. Consequently, total metformin use
could not be comprehensively recorded. This leads to the
under-measurement of metformin and total glucose-lowering
drug use, and subsequently an over-calculation of the relative
share of novel glucose-lowering drugs among the total use of
glucose-lowering drugs. At the same time, because all novel
glucose-lowering drugs were reimbursed, a complete and
detailed picture of the trends in use of novel glucose-lowering
drugs in Hungary was available for analysis. It should also be
noted that, although the application of DDD/TID makes the
comparison of aggregated medication use of different drug
groups across populations possible, the DDD may differ
from the actual prescribed daily dose [10].
In conclusion, the last 10 years havebroughtmany changes in
the treatment of diabetesmellitus. Since novel glucose-lowering
drugs appeared on the drug market, the use of these drugs has
grown steadily in Hungary. The reimbursement for novel
glucose-lowering drugs and their inclusion in the Hungarian
therapeutic guidelines may be strong contributing factors to
their increasing utilization. At the same time, the growing
consumption of novel glucose-lowering drugs puts a high
financial burdenbothon individuals and thenational healthcare
system. Considering the constant changes in both national and
international guidelines and recommendations, a further
increase in novel glucose-lowering drug utilization is expected.
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